



## Nanobiotix announces 2020 Q4 and annual revenues

February 26, 2021 1:00 PM EST

- **Strong cash position of €119.2M as of December 31, 2020**
- **Successful completion of U.S. initial public offering and listing on the Nasdaq Global Select Market**
- **Publication of promising clinical results and initiation of several clinical studies**

Paris, France; Cambridge, Massachusetts (USA); February 26, 2021 – [NANOBIOTIX](#) (Euronext : NANO – NASDAQ: NBTX – the “ Company), a clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced its revenues for the fourth quarter and full year ended December 31, 2020.

### Full Year 2020 Revenue

	Twelve Months Ended December 31 <sup>st</sup>	
K€	2020	2019
Revenues	50	68
Of which licenses	-	-
Of which services	50	68
Other sales	-	-

### Fourth Quarter 2020 Revenue

In K€	Q4 2020	Q3 2020	Q2 2020	Q1 2020
Revenues	-1.5 <sup>[1]</sup>	14.7	13.4	23.5
Of which licenses	-	-	-	-
Of which services	-1.5	14.7	13.4	23.5

### Full Year and Fourth Quarter 2020 Financial Results

Nanobiotix generated annual revenue of approximately €50K, driven primarily by the charging-back of costs incurred on behalf of PharmaEngine in connection with the Company’s license and collaboration agreement with PharmaEngine. The absence of revenues in the fourth quarter of 2020 is explained by the issuance of a credit note following an annual adjustment.

The Company’s cash and cash equivalents as of December 31<sup>st</sup>, 2020 amounted to €119.2M following completion of a successful U.S. initial public offering on the Nasdaq Global Select Market in December 2020 resulting in total gross proceeds of €93.5 million (\$113.3 million based on an exchange rate of €1.00=\$1.2115). Net proceeds, after deducting underwriting commissions and other offering expenses, were €82.8 million (€100.4 million). Nanobiotix anticipates that its current cash position will be sufficient to fund current operations and planned development activity through the middle of the second quarter of 2023.

### Key Events in Fourth Quarter 2020 and After the Reporting Period

In October 2020, Nanobiotix announced that the first patient had been injected with NBTXR3 in the Company’s phase I trial evaluating NBTXR3 activated by radiation therapy for patients with pancreatic cancer, and that “safe to proceed” notifications had been received from the U.S. Food and Drug Administration (FDA) for two additional trials: (i) a phase I study evaluating NBTXR3 activated by radiation therapy for patients with lung cancer amenable to re-irradiation (Study 2020-0123) and (ii) a phase I study evaluating NBTXR3 activated by radiation therapy with concurrent chemotherapy for patients with esophageal cancer (Study 2020-0122). These studies are being conducted as part of an ongoing clinical collaboration with The University of Texas MD Anderson Cancer Center (MD Anderson).

In November 2020, the Company presented positive first clinical data at the 35<sup>th</sup> Anniversary Annual Meeting of The Society for Immunotherapy of

Cancer (SITC) suggesting that NBTXR3 activated by radiation therapy in combination with pembrolizumab or nivolumab (anti-PD-1 checkpoint inhibitors) could transform anti-PD-1 non-responders into responders.

At SITC, Nanobiotix also published a pre-clinical study revealing that NBTXR3 activated by radiotherapy could under certain circumstances produce a strong abscopal effect without checkpoint inhibitor combination, stimulate adaptive antitumor immunity and increase TCR repertoire diversity in treated tumors compared to radiation therapy alone.

A second pre-clinical study presented at SITC showed that NBTXR3 plus high dose and low dose radiation (RadScopal™) combined with anti-PD-1 and anti-CTLA-4 could significantly improve control of both the primary and secondary tumors, extend survival, and reduce lung metastases in an anti-PD-1 resistant lung cancer *in vivo* model—and the treatment combination was observed to promote an anti-tumor response at both molecular and cellular levels and to produce long-term anti-tumor memory.

Also in November 2020, Nanobiotix announced that the FDA had provided “safe to proceed” notifications for two additional phase II clinical studies with MD Anderson. The first clinical study (Study 2020-0541) targets patients with recurrent or metastatic head and neck squamous cell carcinoma with limited PD-L1 expression, or that are refractory to PD-1 blockade. The second clinical study (Study 2020-0354) targets patients with inoperable locoregional recurrent head and neck squamous cell carcinoma amenable to re-irradiation.

In December 2020, Nanobiotix successfully completed its U.S. initial public offering on the Nasdaq Global Select Market, the operation also included the launch of a placement in Euronext market.

In January 2021, Nanobiotix announced that the first patient has been injected in a phase I study evaluating tumor-agnostic NBTXR3 activated by radiation therapy with concurrent chemotherapy for patients with esophageal cancer (Study 2020-0122).

Also in January 2021, Nanobiotix announced that its wholly-owned subsidiary Curadigm was selected for a new collaboration agreement with Sanofi. Pursuant to Sanofi's selection of a project involving Curadigm's Nanoprimer technology as a promising option to significantly improve gene therapy development, Curadigm entered into a one-year agreement with Sanofi inclusive of direct funding and scientific exchanges. The goal of the project is to establish proof-of-concept for the Nanoprimer as a combination product that could improve treatment outcomes for gene therapy candidates.

## 2021 Financial Agenda

Nanobiotix plans to announce its financial and operating results as follows:

- March 17, 2021 – 2020 Full Annual Results
- April 28, 2021 – Annual General Meeting, Paris, France
- April 30, 2021 – First Quarter 2021 Revenues
- July 16, 2021 – Second Quarter 2021 Revenues
- September 3, 2021 – 2021 Half Year Results
- October 22, 2021 – Third Quarter 2021 Revenue

[\[1\]](#) Annual revenue regularization resulting in the issuance of a credit note in Q4 2020.

## About NANOBOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The company's philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France. The company also has subsidiaries in Cambridge, Massachusetts (United States), France, Spain, Germany and Switzerland.

Nanobiotix has been listed on the regulated market of Euronext in Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020.

Nanobiotix is the owner of more than 30 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system. The company's resources are primarily devoted to the development of its lead product candidate— NBTXR3 —which is the product of its proprietary oncology platform and has already achieved market authorization in Europe for the treatment of patients with soft tissue sarcoma under the brand name Hensify®.

For more information about Nanobiotix, visit us at [www.nanobiotix.com](http://www.nanobiotix.com) or follow us on [LinkedIn](#) and [Twitter](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220104005866/en/): <https://www.businesswire.com/news/home/20220104005866/en/>

*Nanobiotix*

### Communications Department

*Brandon Owens*

*VP, Communications*

+1 (617) 852-4835

[contact@nanobiotix.com](mailto:contact@nanobiotix.com)

### Investor Relations Department

*Kate McNeil*

*SVP, Investor Relations*

+1 (609) 678-7388

[investors@nanobiotix.com](mailto:investors@nanobiotix.com)

*Media Relations*

France – **Ulysse Communication**

Pierre-Louis Germain

+ 33 (0) 6 64 79 97 51  
[plgermain@ulyse-communication.com](mailto:plgermain@ulyse-communication.com)

US – **Porter Novelli**  
Dan Childs  
+1 (781) 888-5106  
[Dan.childs@porternovelli.com](mailto:Dan.childs@porternovelli.com)

Source: Nanobiotix